These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31927584)

  • 1. FluoroCalins: engineered lipocalins with novel binding functions fused to a fluorescent protein for applications in biomolecular imaging and detection.
    Eggenstein E; Richter A; Skerra A
    Protein Eng Des Sel; 2019 Dec; 32(6):289-296. PubMed ID: 31927584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin.
    Gebauer M; Schiefner A; Matschiner G; Skerra A
    J Mol Biol; 2013 Feb; 425(4):780-802. PubMed ID: 23238252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas.
    Albrecht V; Richter A; Pfeiffer S; Gebauer M; Lindner S; Gieser E; Schüller U; Schichor C; Gildehaus FJ; Bartenstein P; Tonn JC; Skerra A; Glass R
    Int J Cancer; 2016 Mar; 138(5):1269-80. PubMed ID: 26421425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein.
    Masuda Y; Yamaguchi S; Suzuki C; Aburatani T; Nagano Y; Miyauchi R; Suzuki E; Yamamura N; Nagatomo K; Ishihara H; Okuno K; Nara F; Matschiner G; Hashimoto R; Takahashi T; Nishizawa T
    J Pharmacol Exp Ther; 2018 May; 365(2):368-378. PubMed ID: 29463608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications.
    Steiner M; Gutbrodt K; Krall N; Neri D
    Bioconjug Chem; 2013 Feb; 24(2):234-41. PubMed ID: 23350721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold.
    Schlehuber S; Skerra A
    Biol Chem; 2001 Sep; 382(9):1335-42. PubMed ID: 11688717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins.
    Richter A; Eggenstein E; Skerra A
    FEBS Lett; 2014 Jan; 588(2):213-8. PubMed ID: 24239535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DiB-splits: nature-guided design of a novel fluorescent labeling split system.
    Bozhanova NG; Gavrikov AS; Mishin AS; Meiler J
    Sci Rep; 2020 Jul; 10(1):11049. PubMed ID: 32632329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA).
    Barinka C; Ptacek J; Richter A; Novakova Z; Morath V; Skerra A
    Protein Eng Des Sel; 2016 Mar; 29(3):105-15. PubMed ID: 26802163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin.
    Schlehuber S; Beste G; Skerra A
    J Mol Biol; 2000 Apr; 297(5):1105-20. PubMed ID: 10764576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The construction of a bifunctional fusion protein consisting of SEC2 and EGFP.
    Liu Y; Xu M; Li X; Sun J; Zhang C; Zhang H
    Biotechnol Appl Biochem; 2014; 61(5):565-71. PubMed ID: 24397332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticalin
    Rothe C; Skerra A
    BioDrugs; 2018 Jun; 32(3):233-243. PubMed ID: 29748739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and characterization of two versions of bifunctional EGFP-sTRAIL fusion proteins.
    Shen J; Wu Y; Shi L; Liu J; Liu S; Guan Z; Yin Z
    Appl Microbiol Biotechnol; 2007 Aug; 76(1):141-9. PubMed ID: 17562041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticalins directed against vascular endothelial growth factor receptor 3 (VEGFR-3) with picomolar affinities show potential for medical therapy and in vivo imaging.
    Richter A; Skerra A
    Biol Chem; 2017 Jan; 398(1):39-55. PubMed ID: 27458663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticalins small engineered binding proteins based on the lipocalin scaffold.
    Gebauer M; Skerra A
    Methods Enzymol; 2012; 503():157-88. PubMed ID: 22230569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.
    Skerra A
    FEBS J; 2008 Jun; 275(11):2677-83. PubMed ID: 18435758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The construction and characterization of a bifunctional EGFP/sAPRIL fusion protein.
    Guan Z; Yao W; Ye J; Dan W; Shen J; Zhang S
    Appl Microbiol Biotechnol; 2007 Jan; 73(5):1114-22. PubMed ID: 17021878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and purification of RHC-EGFP fusion protein and its application in hyaluronic acid assay.
    Duan N; Lv W; Zhu L; Zheng W; Hua Z
    Prep Biochem Biotechnol; 2017 Mar; 47(3):261-267. PubMed ID: 27536858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticalin® proteins: from bench to bedside.
    Deuschle FC; Ilyukhina E; Skerra A
    Expert Opin Biol Ther; 2021 Apr; 21(4):509-518. PubMed ID: 33074019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing the stability and solubility of the glucocorticoid receptor ligand-binding domain by high-throughput library screening.
    Seitz T; Thoma R; Schoch GA; Stihle M; Benz J; D'Arcy B; Wiget A; Ruf A; Hennig M; Sterner R
    J Mol Biol; 2010 Nov; 403(4):562-77. PubMed ID: 20850457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.